| ERR agonist studied for metabolism and endurance. 0.0%7 days | | 0.0% | from$0.018/mg$58.50/bottle | 3 in stock | |
| Dual GIP/GLP-1 agonist studied for metabolic health. 0.0%7 days | | 0.0% | from$1.43/mg$34.20/vial | 17 in stock | |
| Orally active ERR agonist studied in mice as an exercise mimetic; a small molecule, not a peptide. 0.0%7 days | | 0.0% | from$0.13/mg$76.50/bottle | 1 in stock | |
| Triple-agonist next-gen GLP-1 research compound. | | 0.6% down | from$1.98/mg$35.99/vial | 27 in stock | |
| GLP-1 receptor agonist studied for appetite and weight. 0.0%7 days | | 0.0% | from$3.11/mg$62.10/vial | 4 in stock | |
| Body-protective compound studied for tissue and gut repair. | | 2.4% down | from$1.30/mg$25.19/vial | 13 in stock | |
| Research compound studied for mitochondrial and cognitive effects. 0.0%7 days | | 0.0% | from$0.0097/mg$48.60/bottle | 1 in stock | |
| Vitamin B12 studied for energy and metabolic support. 0.0%7 days | | 0.0% | from$0.41/mg$40.50/vial | 2 in stock | |